

Non Small Cell Lung Cancer (NSCLC): Update Bulletin #2

<https://marketpublishers.com/r/N48E4071D4CEN.html>

Date: January 2018

Pages: 0

Price: US\$ 1,095.00 (Single User License)

ID: N48E4071D4CEN

Abstracts

This edition presents key opinion leader (KOL) views on recent developments in the non-small cell lung cancer (NSCLC) market. Topics covered include: the success of the Phase III KEYNOTE-189 trial of Merck & Co.'s Keytruda (pembrolizumab), in combination with chemotherapy, for the first-line treatment of patients with metastatic NSCLC in meeting its co-primary endpoints of overall survival (OS) and progression-free survival (PFS); the presentation of positive data from the Phase III IMpower150 trial of Roche's Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy in the first-line treatment of advanced non-squamous NSCLC at the ESMO Immuno Oncology Congress 2017; Bristol-Myers Squibb's (BMS') CheckMate-227 Phase III trial of Opdivo (nivolumab) in combination with ipilimumab (Yervoy) for the first-line treatment of advanced NSCLC with high tumour mutational burden (TMB) meeting its co-primary endpoint of PFS.

Business Questions:

Will the KEYNOTE-189 trial change the first-line treatment paradigm for NSCLC?

To what extent is Keytruda in combination with chemotherapy already used in the US as a first-line treatment for advanced NSCLC?

What key data will convince oncologists to incorporate Keytruda plus chemotherapy into standard first-line treatment practice?

How do KOLs view the initial data released from the Phase III IMpower150 trial of Roche's Tecentriq (atezolizumab) in combination with Avastin (bevacizumab)?

and chemotherapy?

Which key data will be essential in order for Tecentriq/Avastin/chemotherapy to be incorporated into first-line treatment?

How do KOLs view the toxicity of Tecentriq/Avastin/chemotherapy and how is it perceived in comparison to that of the KEYNOTE-189 regimen?

How do KOLs view the likely uptake of Tecentriq/Avastin/chemotherapy versus Keytruda/chemotherapy in the first-line setting and why?

How do KOLs react to the news of the improvement in PFS in BMS' CheckMate-227 trial of Opdivo plus ipilimumab?

What expectations do KOLs hold in terms of the OS outcome from the CheckMate-227 trial?

How do KOLs view the use of high TMB as a biomarker for the use of Opdivo/ipilimumab and what could enhance its successful incorporation into clinical practice?

How do KOLs view the potential future role of Opdivo/ipilimumab combination therapy in the first-line treatment of NSCLC?

I would like to order

Product name: Non Small Cell Lung Cancer (NSCLC): Update Bulletin #2

Product link: <https://marketpublishers.com/r/N48E4071D4CEN.html>

Price: US\$ 1,095.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N48E4071D4CEN.html>